Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms

Inclusion Criteria: * Adequately understand the study and voluntarily sign the Informed Consent Form. * Have a confirmed histological or cytological diagnosis of neuroendocrine neoplasm. * Have measurable disease based on RECIST 1.1. * Have adequate organ and bone marrow function. * Life expectancy \> 12 weeks. * Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment. Exclusion Criteria: * Other malignant tumors diagnosed within 5 years (excluding effectively treated basal cell carcinoma, cutaneous squamous cell carcinoma, or completely resected in situ cervical/breast cancer). * Concurrent use of other investigational drugs or approved/investigational anti-tumor therapies. * Contraindications to surufatinib: active bleeding, ulcers, intestinal perforation/obstruction, uncontrolled hypertension, grade III-IV cardiac insufficiency, \<30 days post-major surgery, or severe hepatic/renal impairment. * Pregnant (positive pre-treatment pregnancy test) or lactating females. * Massive pleural effusion/ascites requiring drainage. * Other diseases/abnormalities (metabolic, physical, or laboratory) deemed by the investigator to preclude study drug use.